Mario Haddad, MD
Internal Medicine · San Juan, PRNPI 1750386652
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,153 and has fallen 82.8% since, to $199 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$794
- Johnson & Johnson$624
- Boehringer Ingelheim$524
- PBG Puerto Rico LLC$408
- Sanofi-aventis U.S. LLC$320
- E.r. Squibb & Sons, L.L.C.$285
- plus $945 from 10 others
What the payments were for
- Food & beverage$3,894100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $794 |
| Johnson & Johnson | 24 | $624 |
| Boehringer Ingelheim | 19 | $524 |
| PBG Puerto Rico LLC | 21 | $408 |
| Sanofi-aventis U.S. LLC | 16 | $320 |
| E.r. Squibb & Sons, L.L.C. | 12 | $285 |
| Merck | 14 | $263 |
| Endologix LLC | 1 | $174 |
| Eli Lilly Export S.A. Puerto Rico Branch | 7 | $164 |
| GSK | 6 | $139 |
| Pfizer Pharmaceuticals LLC | 5 | $57 |
| Exact Sciences | 2 | $50 |
| Dexcom, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $25 |
| Biotronik Inc. | 1 | $24 |
| Davol Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,900 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 194 | $145,439 |
| JanumetSitagliptin Phos/Metformin Hcl | 135 | $98,062 |
| FarxigaDapagliflozin Propanediol | 110 | $95,815 |
| JardianceEmpagliflozin | 98 | $94,615 |
| XareltoRivaroxaban | 90 | $94,163 |
| SynjardyEmpagliflozin/Metformin Hcl | 149 | $92,767 |
| SynthroidLevothyroxine Sodium | 593 | $73,542 |
| JanuviaSitagliptin Phosphate | 53 | $53,778 |
| TradjentaLinagliptin | 35 | $36,433 |
| EntrestoSacubitril/Valsartan | 40 | $35,495 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 45 | $29,512 |
| LantusInsulin Glargine,hum.Rec.Anlog | 252 | $25,569 |
| OzempicSemaglutide | 23 | $25,187 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $24,540 |
| TrulicityDulaglutide | 17 | $17,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Tradjenta, Synjardy Xr, Glyxambi | $524 | $290,941376 claims |
| MerckJanumet, Januvia, Janumet Xr | $263 | $181,352233 claims |
| AstraZenecaFarxiga, Brilinta | $794 | $106,952125 claims |
| Johnson & JohnsonXarelto | $624 | $94,16390 claims |
| Sanofi-aventis U.S. LLCLantus | $320 | $25,569252 claims |
| Novo NordiskOzempic | $25 | $25,18723 claims |
| GSKBreo Ellipta | $139 | $5,78214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in San Juan
- Ricardo FernandezSan Juan$351K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Roberto Calderon SantiagoSan Juan$20K
- Natalia Almodovar ArbeloSan Juan$9K
- Jeremy FelicianoSan Juan$8K
- Porfirio Diaz-RodriguezSan Juan$8K
- Pedro del Valle de TomasSan Juan$7K
- Rafael Figueroa NavarroSan Juan$6K
- Amilcar Torres FigueroaSan Juan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.